Atypical cytostatic mechanism of N-1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis
NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2
Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas
A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer
Topical henna for capecitabine induced hand–foot syndrome
A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)